Session: Immunoadsorption in severely ill ME/CFS patients

Dr Georg Schlieper discussed immunoadsorption treatment in patients with very severe ME/CFS. A series of case studies showed improvement in individual patients with Long COVID (Bell score change from 30 to 60), post-vaccine syndrome (Bell score from 20 to 70), or post-COVID ME/CFS (Bell score from 0 to 20). However, since there has been no control group to date, a randomised controlled clinical trial must first be conducted before definitive statements on efficacy can be made. Further research is needed to examine the mechanisms involved to understand why some patients benefit from immunoadsorption and others do not.

​